Increased production of circulating soluble co-stimulatory molecules CTLA-4, CD28 and CD80 in patients with rheumatoid arthritis

Cao, Ju; Zou, Lin; luo, Peixin; Chen, Pu; Zhang, Liping

doi:10.1016/j.intimp.2012.08.004

Cited by 36 publications

(23 citation statements)

References 35 publications

(39 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Aberrant expression of soluble co-stimulatory molecules is associated with persistent activation of T cells in autoimmune diseases [20] – [23] . However, the role of these soluble molecules during transplantation is not fully understood.…”

Section: Introductionmentioning

confidence: 99%

Soluble Co-Signaling Molecules Predict Long-Term Graft Outcome in Kidney-Transplanted Patients

et al. 2014

View full text Add to dashboard Cite

Co-signaling molecules are responsible for full T-cell activation after solid organ transplantation. Their increased expression can lead to the release of a soluble form that can modulate the immune response post-transplantation. We analyzed the presence of co-signaling molecules (sCD30, sCD40, sCD137, sCTLA-4, sCD80, sCD28, sCD40L, sPD-1, and sPD-L1) in serum from kidney-transplanted patients (n = 59) obtained at different times (before transplantation, and 15 days, 3 months and 1 year post-transplantation) and their contribution to graft outcome was evaluated using principal component analysis. Before transplantation, high levels of soluble co-signaling molecules (mainly sCD30, sCD137 and sCD40) were detected in all patients. These molecules were modulated soon after receiving an allograft but never attained similar levels to those of healthy controls. A signature based on the determination of six soluble co-stimulatory (sCD30, sCD40, sCD137 and sCD40L) and co-inhibitory (sPD-1 and sPD-L1) molecules at 3 months post-transplantation allowed a group of patients to be identified (27.12%) with a worse long-term graft outcome. Patients with high levels of soluble molecules showed a progressive and gradual deterioration of kidney function (increased creatinine and proteinuria levels and decreased estimated glomerular filtration rate) over time and a higher risk of graft loss at 6 years post-transplantation than patients with low levels of these molecules (62.55% versus 5.14%, p<0.001). Thus, our data show an aberrant expression of soluble co-signaling molecules in kidney-transplanted patients whose quantification at 3 months post-transplantation might be a useful biomarker of immune status and help to predict long-term graft evolution.

show abstract

Section: Introductionmentioning

confidence: 99%

Soluble Co-Signaling Molecules Predict Long-Term Graft Outcome in Kidney-Transplanted Patients

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Defects in coinhibitory molecules may cause autoimmune disorders. The sCTLA-4 molecule and various other costimulatory signal molecules may have a role in the pathogenesis of AS and correlate with clinical findings (15). This hypothesis was initially supported by the demonstration of lymphocyte hyperactivation in CTLA-4-deficient mice.…”

Section: Discussionmentioning

confidence: 92%

Serum sCTLA-4 levels and clinical manifestations in ankylosing spondylitis patients

et al. 2018

View full text Add to dashboard Cite

“…The sCTLA‐4 has binding capacity to CD80/CD86. The elevated levels of sCTLA‐4 have been found to be related to various autoimmune disorders, including rheumatoid arthritis , Crohn's disease , and celiac disease , and were considered as a potential new biomarker for the diagnoses of autoimmune diseases . Additionally, in a recent study, it was shown to be associated with inflammatory markers such as IL‐6, TNF‐alpha, IFN‐gamma, and IL‐8 .…”

Section: Discussionmentioning

confidence: 99%

The influence of CTLA‐4 single nucleotide polymorphisms on acute kidney allograft rejection in Turkish patients

Ruhı

Sallakçı

Yegin

et al. 2015

Clinical Transplantation

View full text Add to dashboard Cite

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is a cell surface protein, which down-regulates the immune response at CTLA-4/CD28/B7 pathway. We aimed to investigate the influence of the -318 C/T, +49 A/G, -1661 A/G and CT60A/G, and CTLA-4 gene polymorphisms on acute rejection of kidney allograft in Turkish patients. The study design was a case-control study that consists of three groups: Group 1 (n = 34) represented the kidney transplant (Ktx) recipients who experienced acute rejection, Group 2 (n = 47) was randomly assigned Ktx recipients without acute rejection, and Group 3 (n = 50) consisting of healthy volunteers to evaluate the normal genomic distribution. The polymerase chain reaction-restriction fragment length polymorphism technique was used to determine the polymorphisms. Genotype and allele frequencies among three groups denoted similar distributions for +49 A/G, -1661 A/G, and CT60A/G. Conversely, -318 C/T genotype was three times more frequent in the acute rejection group than in the non-rejection group (OR = 3.45; 95%CI = 1.18-10.1, p = 0.015) and two times more frequent than the healthy control group (OR = 2.45; 95% CI = 0.98 - 6.11, p = 0.047). Additionally, having a T allele at -318 position was significantly associated with acute rejection (0.147 vs. 0.043, OR = 3.45; 95% CI = 1.13-10.56, p = 0.02). 318C/T gene polymorphism and T allelic variant were found to be associated with increased acute rejection risk in Turkish kidney allograft recipients.

show abstract

Increased production of circulating soluble co-stimulatory molecules CTLA-4, CD28 and CD80 in patients with rheumatoid arthritis

Cited by 36 publications

References 35 publications

Soluble Co-Signaling Molecules Predict Long-Term Graft Outcome in Kidney-Transplanted Patients

Soluble Co-Signaling Molecules Predict Long-Term Graft Outcome in Kidney-Transplanted Patients

Serum sCTLA-4 levels and clinical manifestations in ankylosing spondylitis patients

The influence of CTLA‐4 single nucleotide polymorphisms on acute kidney allograft rejection in Turkish patients

Contact Info

Product

Resources

About